Core Viewpoint - The company has approved the use of up to RMB 750 million of its own funds for entrusted wealth management, with a focus on low-risk financial products to enhance capital efficiency and profitability [1][18]. Group 1: Wealth Management Products Overview - On February 5, 2026, the company invested RMB 20 million in a wealth management product from Changjiang Securities, with an expected annualized return of 3.4% plus excess returns [4][18]. - On February 3, 2026, the company invested RMB 10 million in a wealth management product from Huatai Securities, with an expected annualized return of 2.15% to 3.2% [5][18]. - On January 27, 2026, the company invested RMB 20 million in a wealth management product from Founder Securities, with an expected annualized return of 4.0% plus excess returns [6][18]. - On January 21, 2026, the company invested RMB 30 million in a wealth management product from Bank of China, with an expected annualized return linked to the seven-day notice deposit rate [8][18]. - On January 12, 2026, the company invested RMB 20 million in a wealth management product from CITIC Securities, with an expected annualized return of 2.35% [10][18]. - On January 9, 2026, the company invested RMB 30 million in a wealth management product from Changjiang Securities, with an expected annualized return of 2.6% plus excess returns [12][18]. - On December 12, 2025, the company invested RMB 30 million in a wealth management product from Changjiang Securities, with an expected annualized return of 2.5% plus excess returns [15][18]. Group 2: Risk Management and Compliance - The company has established a strict management system for entrusted wealth management, including principles, approval authority, decision-making processes, and risk control measures [17]. - The finance department is responsible for daily management, investment control, and auditing of entrusted wealth management activities [17]. - Independent directors and the audit committee have the authority to inspect the entrusted wealth management activities [17]. Group 3: Financial Impact - The company maintains a healthy cash flow and aims to use part of its idle funds for low-risk wealth management to improve capital efficiency and profitability, benefiting shareholders [18]. - As of the announcement date, the company has approximately RMB 612.4 million in outstanding wealth management products, accounting for 30.72% of the latest audited net assets, which is within the authorized limit [18].

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 鉴于潜江永安药业股份有限公司（以下简称"公司"）及子公司总计使用最高额度不超过（含）人民币 7 亿元的自有资金进行委托理财事项的授权即将到期，为提高公司自有闲置资金的利用效率，获取一定的 投资收益，公司于2025年4月28日、2025年6月24日分别召开了第七届董事会第六次临时会议及2024年年 度股东会，审议通过了《关于使用自有资金进行委托理财的议案》，同意公司及子公司总计使用最高额 度不超过（含）人民币 7.5 亿元的自有资金进行委托理财。上述额度可滚动使用，有效期自股东会审议 通过之日起不超过 12 个月，并授权公司管理层具体实施相关事宜。公司根据上述决议，择机购买了相 关理财产品，现将有关情况公告如下： 一、理财产品的主要情况 （一）2025年7月30日，公司出资3000万元，向中国银河证券股份有限公司（以下简称"银河证券"）购 买理财产品，具体情况如下： 1、产品名称：银河盛汇尊享3号集合资产管理计划 2、产品代码：ZX1003 3、产品主要投资范围： ...